Overview

Safety and Efficacy Study of SHAPE Gel in Alopecia Areata

Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of SHAPE Gel applied topically to adult patients with alopecia areata of the scalp.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
TetraLogic Pharmaceuticals
Treatments:
Histone Deacetylase Inhibitors
Criteria
Inclusion Criteria:

- Diagnosis of scalp alopecia areata and scalp hair loss due to alopecia areata for a
minimum of six months and a maximum of two years.

- Patients taking thyroid medication or hormonal therapy must be on a stable dose for 6
months and maintain such throughout the study.

- Willingness to maintain same hair style, including shampoo and hair dye, throughout
the study period.

- Willingness to have a small micro dot tattoo placed to allow for photographic analysis
of treatment and application of study medication.

Exclusion Criteria:

- History of systemic or cutaneous malignancy and/or lymphoproliferative disease, other
than patients with: up to 3 basal cell carcinoma; up to three well differentiated
cutaneous squamous cell carcinoma; and/or cervical intraepithelial neoplasm (CIN),
treated successfully with no evidence of disease, and treated for greater than 6
months prior to study entry.

- Current actinic keratosis on the scalp and/or face

- Nevi or cutaneous lesions thought suspicious for malignancy.

- History of or current gastrointestinal, pulmonary, cardiovascular, genitourinary or
hematological disease, CNS disorders, infectious disease or coagulation disorders that
would preclude participation in and completion of study assessments.

- Positive for hepatitis B surface antigen, HIV or hepatitis C.

- Co-existent androgenetic alopecia: in males: Norwood-Hamilton stage IV, V or VI; in
females: Ludwig stage II or III.

- Unwillingness to discontinue use of non-breathable wigs, weaves or shaving of scalp
throughout course of study.